VOGLIBOSE 0.2mg. IP

An alpha-glucosidase inhibitor that lowers blood sugar levels in type 2 diabetes mellitus patients. (Ajay S. Dabhi, 2013) A potential therapeutic option that treats postprandial hyperglycemia in diabetic patients. Delays the digestion and absorption of carbohydrates, thereby inhibiting postprandial hyperglycemia and hyperinsulinemia. (Xiaolong Chen, 2006) Effectively prevents the progression of impaired glucose tolerance to type 2 diabetes. (Kawamori, 2010) Impedes absorption of carbohydrates and reduces glucose levels in Type 2 diabetes patients. (Mayumi Negishi, 2008) A more potent and well-tolerant alpha glycosisade inhibitor as compared to acarbose and miglitol. (Ajay S. Dabhi, 2013) An effective and generally well-tolerated drug in a wide range of Type 2 diabetic mellitus patients. (Ajay S. Dabhi, 2013) Lowers the daily glycemic fluctuations and inhibits overwork of the pancreatic beta-cells. (K Matsumoto, 1998) A beneficial medicament in elderly patients and in those with hepatic impairment or mild to moderate renal function impairments when other anti-diabetic agents are contraindicated. (Ajay S. Dabhi, 2013)